A Study of HLD-0117 in Patients With Metastatic Breast Cancer

Summary

Assessment of the safety and efficacy of HLD-0117 as monotherapy in patients with estrogen receptor positive (ER+) metastatic breast cancer (MBC) or locally advanced breast cancer that have progressed on prior systemic therapies.

Timeline

Start

2026-04-09

Primary completion

2028-04-30

Completion

2028-04-30

Drugs

Indications